Compare Amplitude Inc (AMPL) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amplitude Inc vs Incyte Corporation — how do they compare? Amplitude Inc trades at $12.37 (market cap $1.59B), while Incyte Corporation trades at $120.95 (market cap $24.54B). The key difference: Incyte Corporation is far larger — about 15.4× Amplitude Inc's market cap, and Amplitude Inc is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals.
| AMPL | INCY | |
|---|---|---|
Market Cap | $1.59B | $24.54B |
Sector | Technology | Health |
52-Week High | $12.69 | $129.93 |
52-Week Low | $5.61 | $81.61 |
Enterprise Value | $1.45B | $20.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amplitude (AMPL) trades at $12.19, up 8.26% over 24 hours, with strong technical momentum indicated by bullish moving averages. The company shows robust revenue growth, reaching $343.21 million in 2025, but continues to report net losses with a -26.59% margin. Recent news highlights AI-driven growth initiatives and enterprise customer expansion as key catalysts.
While analyst consensus remains bullish with 67% buy ratings and a $12.08 price target, persistent profitability challenges and ongoing legal investigations present significant risks. The stock's current valuation at 4.49x sales appears reasonable given growth prospects, but sustained losses require careful monitoring of margin improvement efforts.
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amplitude Inc
Amplitude Inc is pioneering a new category of software called digital optimization. The company's digital optimization system serves as the command center for businesses to connect digital products to business outcomes.
Read more on AMPL →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
